Compare AHMA & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHMA | RNXT |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United Arab Emirates | United States |
| Employees | 44 | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.7M | 37.0M |
| IPO Year | N/A | 2021 |
| Metric | AHMA | RNXT |
|---|---|---|
| Price | $1.05 | $0.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | ★ 324.0K | 311.0K |
| Earning Date | 05-22-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | N/A | $279.78 |
| P/E Ratio | $180.72 | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $0.76 | $0.70 |
| 52 Week High | $39.50 | $1.45 |
| Indicator | AHMA | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 38.56 | 48.40 |
| Support Level | $1.04 | $0.89 |
| Resistance Level | $1.40 | $1.07 |
| Average True Range (ATR) | 0.10 | 0.07 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 5.56 | 54.09 |
Ambitions Enterprise Management Co LLC, through its subsidiaries in the UAE, operates as a tour operator, travel agency, and event planning and management services provider. It provides two lines of services, namely, MICE management, a comprehensive coordination and organization of events, and one-stop tourism, a comprehensive travel product that is designed to provide tourists with all the necessary components of a trip in a single and convenient package, which typically include transportation, accommodations, meals, and guided tours or activities.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.